Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy
Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of acute ischemic stroke. This designation highlights the FDA’s recognition of PP-007’s potential to address critical needs in stroke treatment. The therapy is currently under evaluation in the ongoing HEMERA-1 clinical trial in the United States, focused on assessing its safety and efficacy.
With over 700,000 ischemic strokes occurring each year in the U.S. ...
